FindTrial
Sign In

In patients with prolonged liver disease and taking propranolol tablets who develop bacterial infection of the liquid surrounding the stomach, we want to study how many of them will develop kidney problem and how many of them will be alive after 28 days

Progressive AKI and 28-day survival in patients with cirrhosis and spontaneous bacterial peritonitis on beta blockers-a prospective observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/076479
Enrollment
112
Registered
2024-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: NIL: NIL

Sponsors

Intramural fund
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria for group1: Patients with cirrhosis and spontaneous bacterial peritonitis who were on propranolol, admitted in the wards of Medical Gastroenterology and Medicine during the study period. Inclusion criteria for group2: Patients with cirrhosis and spontaneous bacterial peritonitis who were not on propranolol, admitted in the wards of Medical Gastroenterology and Medicine during the study period.

Exclusion criteria

Exclusion criteria: Patients who already received antibiotic within 7days of diagnosis of SBP Variceal bleed within 7days of diagnosis of SBP Chronic kidney disease Intrinsic renal disease Refractory ascites Hepatocellular carcinoma Peritoneal carcinomatosis Peritoneal tuberculosis Pancreatitis Bleeding into ascitic fluid Heart Failure Concurrent other malignancies Human immunodeficiency virus infection Use of immunosuppressive agents

Design outcomes

Primary

MeasureTime frame
To study the frequency of progressive AKI and 28-day survival in those patients with cirrhosis and spontaneous bacterial peritonitis, who are receiving beta blockers.Timepoint: 2,7 and 28days—

Secondary

MeasureTime frame
To compare the frequency of progressive AKI and 28-day survival in patients with cirrhosis and spontaneous bacterial peritonitis on beta-blockers when compared to controls.Timepoint: 2,7 and 28days—

Countries

India

Contacts

Public ContactS Abdul Rajak

JIPMER, Pondicherry

sirasapallisivakrishna@gmail.com7382270431

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026